The landscape of tools the World Health Organization (WHO) recommends for the diagnosis, treatment, care and support of people with drug-resistant TB continues to evolve. To help advocates stay up to date, Treatment Action Group (TAG) organized a series of virtual trainings for community and civil society organizations.

On Thursday, July 25th, TAG hosted a training on the basics of drug-resistant TB and the BPaL/M regimen. Drug-Resistant TB Basics covered how drug-resistant TB is defined, how it develops, and how it is treated. The training provided a close look at the BPaL/M regimen and an overview of factors that affect access to treatment and person-centered care. (Slide deck is in the right sidebar.)

On Thursday, November 21st, TAG hosted a training to introduce anticipated updates to the WHO guidelines for the treatment of drug-resistant TB. Putting Drug-Resistant TB Treatment Guidelines Updates in Context for Communities and Civil Society provided a breakdown of new six- and nine-month regimens and provided context for how they are likely to fit into national guidelines and TB programs in practice alongside BPaL/M. (Slide deck is in the right sidebar.)

On Thursday, December 12, TAG hosted a training on  Drug-Resistant TB Treatment and Care in Special Populations. This webinar provided updates for communities and civil society on the latest standards of care for children and adolescents, pregnant women, and people who are incarcerated, on the move, and/or that have comorbid conditions such as HIV and hepatitis C.

On Thursday, February 6, TAG hosted another installment in this community webinar series on drug-resistant TB (DR-TB). For this webinar, Dr. Jen Furin went deep on medications, side effects, interactions and monitoring strategies for people taking these regimens as part of their therapy.

On April 16, 2026, Treatment Action Group (TAG) presented “What TB Treatment advocates need to Know about active TB Drug Safety Monitoring and Management and Pharmacovigilance (aDSM/PV)”. In recent years, a new generation of shorter, all-oral, and effective medicines for drug-resistant tuberculosis (DR-TB) has been recommended by the World Health Organization (WHO). These alternative regimens, which are referred to as BPaL/M, BEAT, and endTB, are shorter and easier on patients than previous drug regimens that include multiple drugs with harsh side effects. However, newer forms of care require close attention to adverse side effects and harmful responses – also known as pharmacovigilance.